PLOS ONE

Human Intestinal Cells Modulate Conjugational Transfer of Multidrug Resistance Plasmids between Clinical *Escherichia coli* Isolates

Ana Manuel Dantas Machado[1], Morten O. A. Sommer[1,2]*

1 Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, 2 Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Hørsholm, Denmark

Abstract

Bacterial conjugation in the human gut microbiota is believed to play a major role in the dissemination of antibiotic resistance genes and virulence plasmids. However, the modulation of bacterial conjugation by the human host remains poorly understood and there is a need for controlled systems to study this process. We established an *in vitro* co-culture system to study the interaction between human intestinal cells and bacteria. We show that the conjugation efficiency of a plasmid encoding an extended spectrum beta-lactamase is reduced when clinical isolates of *Escherichia coli* are co-cultured with human intestinal cells. We show that filtered media from co-cultures contain a factor that reduces conjugation efficiency. Protease treatment of the filtered media eliminates this inhibition of conjugation. This data suggests that a peptide or protein based factor is secreted on the apical side of the intestinal cells exposed to bacteria leading to a two-fold reduction in conjugation efficiency. These results show that human gut epithelial cells can modulate bacterial conjugation and may have relevance to gene exchange in the gut.

Competing Interests: The authors have declared that no competing interests exist.

* Email: msom@bio.dtu.dk

Introduction

The human body is inhabited by a vast number of microorganisms collectively referred to as the microbiota [1–3]. The microbiota colonizes every surface of the human body exposed to the environment, including skin, genitourinary, respiratory, and gastrointestinal tracts [3–5], with the gastrointestinal tract as the most heavily colonized site in the body [6,7]. The relationship between the host and its resident microbiota can be mutually beneficial and the microbiota has substantial impact on human health, including dietary and nutritional processing, prevention of pathogen invasion and immune system maturation [8–10].

Communication between the human host and its microbiota is necessary for many of these processes. The intestine provides an extensive platform for intercellular signaling between the microbiota, the host, and incoming pathogens. Indeed, intestinal microorganisms secrete molecules that can be sensed by their host, and can also sense host-produced molecules [11,12]. In addition to such host-microbiota metabolic and signaling interactions, microorganisms also exchange genetic material between them in the gastrointestinal tract. This process of horizontal gene transfer has been implicated in clinical problems with antibiotic resistance [13,14]. In fact, exchange of antibiotic resistance genes between resistant and susceptible bacteria have been studied in animals and humans [15–17].

Horizontal gene transfer can occur through transformation, transduction, and conjugation. It is currently believed that conjugation is the major contributor to the dissemination of antibiotic resistance genes [18]. Conjugation involves the transfer of DNA between cells in a contact-dependent fashion. Plasmids, conjugative transposons, regions of bacterial chromosomes, and integrative and conjugative elements can be transferred via conjugation between remotely related organisms [19–23]. While conjugation is recognized to play a key role in the dissemination of antibiotic resistance genes, the influence of the human host on conjugational transfer remains controversial. Several studies have reported inefficient enterobacterial conjugation in intestinal extracts from mice [24] and in the mammalian gut [25,26]. Yet, other reports identified higher rates of conjugation in the gut [27,28]. Several factors, including pathogen-driven inflammatory responses occurring in the gut could explain some of these disagreements [29–34]. However, there is a need to establish well-controlled model systems in order to improve our understanding of the specific host derived factors that affect bacterial conjugation [35]. In this study we establish such an *in vitro* experimental system using intestinal epithelial cells in co-culture with clinical *E. coli* isolates able to donate and receive an ESBL (extended spectrum beta-lactamase) plasmid. We used this system to determine the impact of human intestinal cells on bacterial conjugation and discovered that an unknown protein or peptide based factor is secreted by intestinal cells reducing the efficiency of bacterial conjugation.

Figure 1. Bacterial conjugation efficiency after co-culture with intestinal cells. (A) Experimental setting. Overview of the setting in a transwell filter and zoom from an area of the filter. In orange and blue are depicted the donor and recipient *E. coli* strains when co-cultured with the intestinal cells without prior treatment. Transconjugants are in green. (B) Efficiency of conjugation after 2 hours of culture of donor and recipient *E. coli* in the presence or absence (w/o) of differentiated intestinal cells, Caco-2. Means ± SEM. Representative of five (with Caco-2 cells) and three (without Caco-2 cells) independent experiments. *, statistically significant from culture with Caco-2 cells (Student's *t* test; *p* = 0.023).
doi:10.1371/journal.pone.0100739.g001

Materials and Methods

Cell culture, *E. coli* strains, and growth conditions

Human Caco-2 colorectal adenocarcinoma cells (ECACC 86010202) were grown in transwell filters (Corning) and maintained in Minimal Essential Media (MEM) (Life Technologies) supplemented with 20% fetal bovine serum, 25 µg/mL gentamycin (Sigma), and 0.1 mM non-essential amino acids (Sigma) for 21 days until differentiation occurred. The cell line was maintained at 37°C under 5% CO_2 humidified atmosphere.

Co-culture was performed using *E. coli* clinical isolates Ec77 and Ec56 (kind gift from Dr. Kristian Schønning, Hvidovre Hospital). Ec77 has an ESBL plasmid and is considered the donor strain. The recipient strain, Ec56, has a kanamycin resistance gene and a gene encoding red fluorescent protein inserted in its Tn7 site. Ec77 and Ec56 were grown in LB supplemented with cefotaxime 2 µg/ml or kanamycin 40 µg/ml, respectively.

Co-culture of Human Cells

After 21 days of culture, Caco-2 cells were washed three times with phosphate-buffered saline (PBS) 1× and incubated in antibiotic-free medium overnight. *E. coli* colonies were grown overnight and added to the apical side of the intestinal cells at a multiplicity of infection (MOI) of 10 bacteria per cell. Cultures were maintained at 37°C under a 5% CO_2 humidified atmosphere. Control samples were processed similarly in the absence of intestinal cells. After 2 hours of infection, the media from the apical side of the Caco-2 cells was recovered and plated

at the appropriate dilutions in LB plates with cefotaxime 2 µg/ml, kanamycin 40 µg/ml and cefotaxime 2 µg/ml plus kanamycin 40 µg/ml.

Protease Treatment

Using Caco-2 cells, co-culture was performed as previously described. Media from the apical side was collected, filtered and treated with 2 mg/ml protease (unspecific protease from *Streptomyces griseus*; Sigma) for 10 minutes at room temperature. Treatment with 1:100 protease inhibitor cocktail (inhibits serine, cysteine, aspartic proteases and aminopeptidases; Sigma) at room temperature followed. *E. coli* strains Ec56 and Ec77 were then cultured in the protease treated media for 2 hours. Control samples were processed similarly in the absence of protease treatment.

Analysis of Conjugation Efficiency

Conjugation efficiency was calculated in the following manner: number of transconjugants divided by the total number of donor bacteria. Number of transconjugants was calculated by counting the colonies in LB plates with cefotaxime 2 µg/ml plus kanamycin 40 µg/ml. Total number of donor bacteria was calculated by counting the colonies in LB plates with cefotaxime 2 µg/ml.

Statistical analysis

Conjugation efficiency results were expressed as mean ± SEM of at least three independent experiments and analyzed by

Figure 2. Bacterial conjugation efficiency after culture with media from pre-infected intestinal cells. (A) Experimental setting. In orange and blue are depicted the donor and recipient *E. coli* strains when co-cultured with the intestinal cells and in the filtered media. Transconjugants are in green. (B) Efficiency of conjugation after 2 hours of culture of donor and recipient *E. coli* in culture media that had previously been cultured with or without *E. coli* in the presence or absence (w/o) of differentiated intestinal cells, Caco-2. Means ± SEM. Representative of three (with Caco-2 cells), five (without Caco-2 cells) and four (with Caco-2 cells and without initial pre-infection with *E. coli*) independent experiments. *, statistically significant from culture with pre-infected Caco-2 cells (Student's *t* test; $p = 0.013$, for without Caco-2 cells; $p = 0.0065$, for with Caco-2 cells without pre-infection).
doi:10.1371/journal.pone.0100739.g002

Student's *t* test. The differences between data sets were considered significant at *P* values <0.05.

Results

Bacterial conjugation efficiency is lower in the presence of intestinal epithelial cells

In order to study the potential influence of human intestinal cells on the ability of bacteria to transfer genetic material between them, we used two *E. coli* clinical isolates. The donor strain harbors an ESBL plasmid and the recipient strain has a kanamycin resistance gene and a gene encoding red fluorescent protein inserted in its Tn7 site. The strains were cultured for 2 hours in the presence or absence of differentiated intestinal epithelial cells (Fig. 1A). The intestinal epithelial cells were not exposed to any prior treatment before co-culture with *E. coli*. After this period of co-culture it was observed that conjugation efficiency of bacteria cultured in the presence of the intestinal epithelial cells (4.51×10^{-5}) presented a two-fold decrease compared to when cultured in the absence of intestinal cells (8.4×10^{-5}; $p = 0.023$) (Fig. 1B). These results show that the presence of intestinal cells decreases the ability of these bacterial strains to perform plasmid conjugation. We recovered a similar number of donor, recipient and transconjugant bacteria after 2 hours in the presence or absence of intestinal cells (Table S1). This observation indicated that the decrease in bacterial conjugation was not due to bacterial killing induced by the intestinal cells.

To test whether the reduced conjugation efficiency was dependent on direct contact with the differentiated epithelial cells, we co-cultured *E. coli* donor and recipient strains for 2 hours in the presence or absence of differentiated intestinal epithelial cells. The media from the apical side of the intestinal cells, which represent the intestinal lumen, was recovered and filtered. Fresh donor and recipient strains were co-cultured for 2 hours in the filtered media and the conjugation efficiency was quantified (Fig. 2A). In this set of experiments we also observed a significantly lower conjugation efficiency in the media that had previously been in contact with intestinal cells (3.45×10^{-5}) compared to the media that had not been in contact with the intestinal cells (5.89×10^{-5}; $p = 0.013$) (Fig. 2B). The efficiency of conjugation in the media that had been in contact with pre-infected intestinal cells was also significantly lower compared to the efficiency of conjugation in the media that had been in contact with intestinal cells where no pre-infection occurred (6.08×10^{-5}; $p = 0.0065$) (Fig. 2B). In view of these results we suggest that upon culture with bacteria, intestinal cells secrete an unknown factor that decreases the ability of bacterial cells to perform conjugation.

Similar experiments were performed with the media from the basal side of the intestinal cells. However, no effect was observed on the conjugation efficiency of the bacterial strains (Fig. S1). Therefore we suggest that the unknown factor secreted by the intestinal cells that has an influence on the conjugation efficiency is secreted by the apical side of the intestinal cells.

Figure 3. Bacterial conjugation efficiency after culture with protease-treated media from pre-infected intestinal cells. (A) Experimental setting. In orange and blue are depicted the donor and recipient *E. coli* strains when co-cultured with the intestinal cells and in the filtered media. Transconjugants are in green. (B) Frequency of conjugation after 2 hours of culture of donor and recipient *E. coli* in culture media that had previously been cultured with *E. coli* in the presence of differentiated intestinal cells, Caco-2. In this media a protease treatment was applied before the second culture of donor and recipient *E. coli* strains. W/o Protease: without protease treatment. Means $\pm$ SEM. Representative of three independent experiments. *, statistically significant from protease treatment (Student's *t* test; $p = 0.0084$).
doi:10.1371/journal.pone.0100739.g003

Bacterial conjugation is impaired by an unknown peptide or protein secreted by intestinal cells

We wanted to determine if the unknown factor reducing conjugation efficiency, secreted by the intestinal cells when in culture with bacteria, was a protein or peptide based factor. To test this we co-cultured intestinal cells with donor and recipient *E. coli* strains for 2 hours. Media from the apical side of the intestinal cells was recovered, filtered, and treated with an unspecific protease from *Streptomyces griseus*. After treatment, donor and recipient *E. coli* strains were cultured in the media for 2 hours (Fig. 3A). It was observed that in the media that had been treated with protease there was a significantly higher conjugation efficiency (7.48×10^{-5}) compared to the media that had not been subjected to the treatment (4.83×10^{-5}; $p = 0.0084$) (Fig. 3B). Therefore we suggest that the unknown factor secreted by the intestinal cells which induces lower conjugation efficiency is a peptide or protein, as protease treatment inhibits the effect of the secreted factor.

Discussion

Bacterial conjugation is considered a major contributor to the dissemination of antibiotic resistance genes in the human gut [18]. Yet, we have a limited understanding of how host factors affect conjugation. We developed an *in vitro* model system that enables controlled investigation of the specific host derived factors that affect bacterial conjugation.

Using this *in vitro* co-culture system we observed that the conjugation efficiency is lowered when clinical *E. coli* isolates are co-cultured with intestinal cells. Our results are in agreement with previous work demonstrating that plasmid transfer between isogenic strains of *E. coli* occurs at a much lower rate in intestinal extracts from mice than in laboratory media [24]. Several other studies report inefficient enterobacterial conjugation in the mammalian gut [25,26]. Yet, other studies identified higher rates of conjugation in the gut [27,28], suggesting that poorly understood *in vivo* factors affect transfer of genetic material [29]. For instance, pathogen-driven inflammatory responses occurring in the gut, mediated by the immune system, have been shown to increase *in vivo* conjugation rates, due to a boost in enterobacterial colonization [29–34].

In our study, after observing that intestinal cells influence bacterial conjugation efficiency we showed that physical contact between intestinal cells and bacteria is not required for the conjugation process *per se*. Instead it is suggested that an unknown factor is secreted on the apical side of the epithelial cells that decreases bacterial conjugation. Similar examples of such communication and interaction between host and bacteria through secreted, diffusible molecules have been reported [36–40]. Finally, we show that protease treatment of the media containing this factor abolishes its inhibitory effect suggesting that the secreted factor is an unknown peptide or protein. Future studies are needed in order to establish the identity of this factor and its relevance *in vivo* as well as to determine the interest of this factor as an adjuvant

in antibiotic treatment in order to prevent or decrease the number of antibiotic resistant infections [41].

Supporting Information

Figure S1 Bacterial conjugation efficiency after co-culture with basal side of intestinal cells. Efficiency of conjugation after 2 hours of culture of donor and recipient *E. coli* in the presence or absence (w/o) of differentiated intestinal cells. *E. coli* was co-cultured on the basal side of the intestinal cells. Means ± SEM. Representative of three independent experiments. (Student's *t* test; $p = 0.987$).
(TIF)

Table S1 Number of donor and recipient *E. coli* colonies recovered after 2 hours of culture in intestinal cell media. After 2 hours of culture, the media from the apical side of the Caco-2 cells was recovered and plated at the appropriate dilutions in LB plates with cefotaxime 2 µg/ml and kanamycin 40 µg/ml. Numbers correspond to the average number of colonies obtained after co-culture with intestinal cells (Fig. 1) and after culture with media from pre-infected intestinal cells (Fig. 2). *p* value was calculated using Student's *t* test between the replicates of "with cells" and "without cells" conditions. (DOCX)

Author Contributions

Conceived and designed the experiments: AMDM MOAS. Performed the experiments: AMDM. Analyzed the data: AMDM. Contributed reagents/materials/analysis tools: AMDM. Wrote the paper: AMDM.

References

1. Kunz C, Kuntz S, Rudloff S (2009) Intestinal flora. Adv Exp Med Biol 639: 67–79.
2. Morelli L (2008) Postnatal development of intestinal microflora as influenced by infant nutrition. J Nutr 138: S1791–S1795.
3. Neish AS (2009) Microbes in gastrointestinal health and disease. Gastroenterology 136: 65–80.
4. Chiller K, Selkin BA, Murakawa GJ (2001) Skin microflora and bacterial infections of the skin. J Invest Dermatol Symp Proc 6: 170–174.
5. Hull MW, Chow AW (2007) Indigenous microflora and innate immunity of the head and neck. Infect Dis Clin North Am 21: 265–282.
6. Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837–848.
7. Whitman WB, Coleman DC, Wiebe WJ (1998) Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 95: 6578–6583.
8. Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313–323.
9. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent *Clostridium difficile*-associated diarrhea. J Clin Gastroenterol 44: 353–360.
10. Muegge BD, Kuczynski J, Knights D, Clemente JC, Gonzaléz A, et al. (2011) Diet drives convergence in gut microbiome functions across mammalian phylogeny and within human. Science 332: 970–974.
11. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, et al. (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82: 3864–3871.
12. Karra E, Batterham RL (2009) The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 316: 120–128.
13. Sommer MOA, Dantas G, Church GM (2009) Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325: 1128–1131.
14. Sommer MOA, Dantas G (2011) Antibiotics and the resistant microbiome. Curr Opin Microbiol 14: 556–563.
15. McConnell MA, Mercer AA, Tannock GW (1991) Transfer of plasmid pAMβI between members of the normal microflora inhabiting the murine digestive tract and modification of the plasmid in a Lactobacillus reuteri host. Microb Ecol Health D 4: 343–355.
16. Lester CH, Frimodt-Moller N, Sorensen TL, Monnet DL, Hammerum AM (2006) *In vivo* transfer of the vanA resistance gene from an *Enterococcus faecium* isolate of animal origin to an *E. faecium* isolate of human origin in the intestines of human volunteers. Antimicrob Agents Chemother 50: 596–599.
17. Trobos M, Lester CH, Olsen JE, Frimodt-Moller N, Hammerum AM (2008) Natural transfer of sulphonamide and ampicillin resistance between *Escherichia coli* residing in the human intestine. J Antimicrob Chemother 63: 80–86.
18. Halary S, Leigh JW, Cheaib B, Lopez P, Bapteste E (2010) Network analyses structure genetic diversity in independent genetic worlds. Proc Natl Acad Sci USA 107: 127–132.
19. Tatum EL, Lederberg J (1947) Gene recombination in the bacterium *Escherichia coli*. J Bacteriol 53: 673–684.
20. Franke AE, Clewell DB (1981) Evidence for a chromosome-borne resistance transposon (Tn916) in *Streptococcus faecalis* that is capable of "conjugal" transfer in the absence of a conjugative plasmid. J Bacteriol 145: 494–502.
21. Burrus V, Pavlovic G, Decaris B, Guedon G (2002) Conjugative transposons: the tip of the iceberg. Mol Microbiol 46: 601–610.
22. Bates S, Cashmore AM, Wilkins BM (1998) IncP plasmids are unusually effective in mediating conjugation of *Escherichia coli* and *Saccharomyces cerevisiae*: involvement of the tra2 mating system. J Bacteriol 180: 6538–6543.
23. Heinemann JA (1991) Genetics of gene transfer between species. Trends Genet 7: 181–185.
24. Licht TR, Christensen BB, Krogfelt KA, Molin S (1999) Plasmid transfer in the animal intestine and other dynamic bacterial populations: the role of community structure and environment. Microbiology 145: 2615–2622.
25. Daniels JB, Call DR, Besser TE (2007) Molecular epidemiology of blaCMY-2 plasmids carried by *Salmonella enterica* and *Escherichia coli* isolates from cattle in the Pacific Northwest. Appl Environm Microbiol 73: 8005–8011.
26. Smet A, Rasschaert G, Martel A, Persoons D, Dewulf J, et al. (2011) *In situ* ESBL conjugation from avian to human *Escherichia coli* during cefotaxime administration. J Appl Microbiol 110: 541–549.
27. Moubareck C, Bourgeois N, Courvalin P, Doucet-Populaire F (2003) Multiple antibiotic resistance gene transfer from animal to human enterococci in the digestive tract of the gnobiotic mice. Antimicrob Agents Chemother 47: 2993–2996.
28. Faure S, Perrin-Guyomard A, Delmas JM, Chatre P, Laurentie M (2010) Transfer of plasmid-mediated CTX-M-9 from *Salmonella enterica* serotype Virchow to *Enterobacteriaceae* in human flora-associated rats treated with cefixime. Antimicrob Agebts Chemother 54: 164–169.
29. Stecher B, Denzler R, Maier L, Bernet F, Sanders MJ, et al. (2012) Gut inflammation can boost horizontal gene transfer between pathogenic and commensal *Enterobacteriaceae*. Proc Natl Acad Sci USA 109: 1269–1274.
30. Lupp C, Robertson ML, Wickham ME, Sekirov I, Campion OL, et al. (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriacea. Cell Host Microbe 2: 119–129.
31. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, et al. (2007) *Salmonella enterica* serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 5: e224.
32. Pédron T, Sansonetti P (2008) Commensals, bacterial pathogens and intestinal inflammation: an intriguing ménage à trois. Cell Host Microbe 3: 344–347.
33. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, et al (2010) Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467: 426–429.
34. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, et al. (2004) High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412–421.
35. Dantas G, Sommer MOA, Degnan PH, Goodman AL (2013) Experimental approaches for defining functional roles of microbes in the gut. Annu Rev Microbiol 67: 459–475.
36. Kasuya M (1964) Transfer of drug resistance between enteric bacteria induced in the mouse intestine. J Bacteriol 88: 322–328.
37. Roberts M, Falkow S (1979) *In vivo* conjugal transfer of R plasmids in *Neisseria gonorrhoeae*. Infect Immun 24: 982–984.
38. Wadolkowski EA, Laux DC, Cohen PS (1988) Colonization of the streptomycin treated mouse large intestine by a human fecal *Escherichia coli* strain: role of growth in mucus. Infect Immun 56: 1030–1035.
39. Poulsen LK, Licht TR, Rang C, Krogfelt KA, Molin S (1995) Physiological state of *Escherichia coli* BJ4 growing in the large intestines of streptomycin-treated mice. J Bacteriol 177: 5840–5845.
40. Licht TR, Tolker-Nielsen T, Holmstrøm K, Krogfelt KA, Molin S (1999) Inhibition of *Escherichia coli* precursor-16A rRNA processing by mouse intestinal contents. Environ Microbiol 1: 23–32.
41. Baquero F, Coque TM, de la Cruz F (2011) Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother 52: 3649–3660.